Omari Gates
Essure is a permanent birth control device that was offered as an alternative to tubal ligation. It was first manufactured by Conceptus Inc., which was later purchased by Bayer HealthCare. Essure was marketed as a safe, effective, non-surgical, and permanent form of birth control. However, in Australia, it is no longer being manufactured or distributed. In 2018, the Therapeutic Goods Administration (TGA) received 59 adverse event reports relating to women implanted with the device, including changes in menstrual bleeding, unintended pregnancy, chronic pain, and allergic reactions. As a result, the TGA imposed additional requirements on Bayer to monitor and report adverse events, and in 2017, the TGA banned vaginal mesh implants, including Essure. Australian women who suffered complications from the device have joined a class action lawsuit against Bayer, and the implant has since been recalled from the Australian market.
| Characteristics | Values |
|---|---|
| Essure Banned in Australia | Yes |
| Year of Ban | 2017 |
| Reason for Ban | Adverse Effects |
| Number of Women Impacted | 7,000 |
| Number of Adverse Event Reports | 59 |
| Side Effects | Irregular Periods, Pelvic or Abdominal Pain, Reduced Libido, Muscle Pain, Hair Loss, Severe Menstrual Bleeding, Chronic Fatigue, Ovarian Pain, Allergies, Unintended Pregnancy, Chronic Pain, Perforation, Migration of the Device |
| Required Action for Affected Women | Surgery, Hysterectomy |
| Legal Action | Class Action Lawsuit |
| Manufacturer | Bayer |
| Year of Launch | 1999 |
| Type of Device | Permanent Birth Control Implant |
Explore related products
What You'll Learn
Essure implant complications
Essure is a permanent birth control implant for non-surgical female sterilisation. It was approved by the U.S. Food and Drug Administration (FDA) in 2002. The implant works by inserting a sharp metal coil into each fallopian tube, generating enough scar tissue to block sperm from reaching an egg.
Despite the success rate of the Essure device, its use exposes patients to a low risk of complications and malfunctions. Complications associated with Essure implants are rarely detected during the procedure and can frequently be asymptomatic in the post-procedural phase. The most common complication is patient or physician non-compliance, such as the failure to return for the three-month hysterosalpingography (HSG) follow-up. Other complications include structural abnormalities, such as insert fracture or stretching of the proximal outer coil, which usually occur during the procedure and require immediate device removal.
Women who have used the device have reported a range of adverse effects, including irregular periods, pelvic or abdominal pain, reduced libido, muscle pain, hair loss, severe menstrual bleeding, chronic fatigue, and stabbing ovarian pain. In some cases, the implant can cause serious side effects, such as organ perforation, coils moving to the abdominal or pelvic cavity, persistent pain, and allergic reactions, which can lead to the need for device removal. In some cases, multiple surgeries have been required to remove the device.
In 2018, a class action lawsuit was filed in Australia by women who had suffered severe complications from the Essure device. As a result, the Therapeutic Goods Administration banned Essure in Australia in 2019. Bayer, the manufacturer of Essure, also recalled the implant from sale in Australia and discontinued its distribution worldwide in 2018.
Primary Education in Australia: Government Schools Count
You may want to see also
Explore related products
Essure banned in Australia
Essure, a permanent birth control device, has been at the centre of a class action by Australian women who suffered adverse effects from the device. The device was implanted in the fallopian tubes and was marketed as an effective, non-surgical, and permanent form of birth control. However, women who underwent the Essure implant procedure reported experiencing numerous serious and often debilitating side effects, including irregular periods, pelvic or abdominal pain, reduced libido, muscle pain, hair loss, severe menstrual bleeding, chronic fatigue, and stabbing ovarian pain. In some cases, the symptoms were so severe that women required a complete hysterectomy.
In response to the reports of adverse effects, the Therapeutic Goods Administration (TGA) imposed extra requirements on the manufacturer, Bayer, in 2015 to monitor and report the rate of adverse events related to Essure. The device was also put under review by US health authorities. Despite these measures, thousands of women in Australia were impacted by the device, with many requiring surgery, including hysterectomy, to remove it.
In 2017, the TGA banned vaginal mesh implants in Australia, including Essure, which was first approved almost two decades earlier. The medical watchdog found that the risks of vaginal mesh implants far outweighed the benefits, and the product was discontinued in Australia for business reasons. The TGA also issued a hazard alert for Essure and recalled unused stock, effectively banning the device in the country.
The movement to ban Essure in Australia gained support from US legal campaigner Erin Brockovich, who backed the Australian class action. More than 16,000 lawsuits have been filed against Bayer, alleging that the company continued to promote the device as safe and effective despite knowing about the serious injuries it could cause. As a result of the class action and growing evidence of the device's harm, Essure is now a banned device in Australia.
A Long Haul: 24 Hours to Australia and Why
You may want to see also
Explore related products
Essure class action lawsuit
In Australia, more than 1,400 women launched a class action lawsuit against Bayer, the maker of the Essure contraceptive device. The lawsuit was filed in the Supreme Court of Victoria in 2019 on behalf of women who received the implant prior to 31 December 2018. The plaintiffs alleged that Bayer breached its duty of care and obligations under Australian consumer protection laws, and that the device was defective, poorly designed, and caused a range of debilitating symptoms and illnesses, including chronic pelvic pain, abnormal uterine bleeding, and allergies. Some women also required hysterectomies to remove the implant.
In response, Bayer stood by the product, citing an extensive body of research, including clinical trials and studies involving a large number of women. The company stated that the health and well-being of women who use their products are their greatest priority.
On 10 December 2024, Justice Keogh of the Supreme Court of Victoria ruled against the plaintiffs, finding that they had failed to prove that Bayer was liable for the injuries pleaded. The decision was criticised by some, including the Victorian Premier, especially since Bayer had settled a similar claim in the United States for US$1.6 billion. However, it was noted that the relevant US laws are different from those in Australia, and the settlement of the US claim may not have a significant impact on the litigation in Australian courts.
Following the judgment, the representative plaintiff decided not to appeal, and the matter was listed for a hearing on 1 May 2025.
Executive Power: Australia's Governing Branch Explained
You may want to see also
Explore related products
Essure adverse effects
Essure is a form of non-surgical, permanent birth control for women. It is a 4-cm-long flexible device consisting of outer nitinol coils and an inner component of polyethelene terephthalate and stainless steel. The procedure involves placing a device in each fallopian tube to create a barrier that keeps sperm from reaching the eggs and prevents conception.
While Essure is an effective sterilization method, there have been reports of adverse effects and negative patient experiences. In Australia, the Therapeutic Goods Administration (TGA) received 59 adverse event reports, including changes in menstrual bleeding, unintended pregnancy, chronic pain, perforation, migration of the device, and allergy/hypersensitivity or immune-type reactions. Some women required surgery, including hysterectomy, to remove the device. Other reported adverse effects include hair loss, severe menstrual bleeding, chronic fatigue, irregular periods, pelvic or abdominal pain, reduced libido, muscle pain, dental problems, autoimmune disorders, and painful sex.
In 2017, the TGA banned vaginal mesh implants in Australia, including Essure, due to the risks of chronic, debilitating pain and the impact on women's lives. A class action has been launched in Australia by women who suffered severe complications and adverse effects from the device, with some requiring a complete hysterectomy. Bayer, the manufacturer of Essure, stopped selling the device in the United States in 2018 and paid $1.6 billion to settle thousands of Essure claims involving device-related injuries.
The adverse effects of Essure have been well-documented, and the manufacturer has been subject to criticism and legal action in various countries, including Australia. The risks associated with Essure have resulted in its discontinuation and ban in several countries, including Australia, due to the potential for severe and life-changing impacts on women's health and quality of life.
Australian Government's Apology to the Stolen Generations: A Historic Moment
You may want to see also
Explore related products
Essure manufacturer sued
Essure, a permanent birth control device, was manufactured by Conceptus, which was purchased by Bayer Healthcare in 2013. The device was designed to be inserted into each of the fallopian tubes, creating enough scar tissue to block sperm from reaching the egg.
However, thousands of women who had the Essure implant suffered from severe complications, including irregular periods, pelvic or abdominal pain, reduced libido, muscle pain, hair loss, severe menstrual bleeding, chronic fatigue, and stabbing ovarian pain. In some cases, the side effects were so severe that women required hysterectomies to remove the device. Many women also reported that the device broke into pieces and migrated from the fallopian tubes, perforating organs and causing internal damage.
As a result of these complications, lawsuits were filed against Bayer, alleging that the company failed to disclose the potential side effects and risks associated with the device. In 2020, Bayer settled the majority of the Essure lawsuits, agreeing to pay $1.6 billion to resolve approximately 39,000 claims. However, some women have continued to file lawsuits against Bayer, seeking compensation for their pain and suffering.
Airlines Flying from Australia to Spain: Comprehensive Guide
You may want to see also
Frequently asked questions
Yes, Essure was banned in Australia in 2017.
Essure is a permanent birth control device offered as an alternative to tubal ligation. It is a sharp metal coil inserted into each fallopian tube, generating enough scar tissue to block sperm from reaching an egg.
Essure was banned in Australia after thousands of women complained of adverse effects, including chronic pain, heavy menstrual bleeding, hair loss, and severe menstrual bleeding.
Following the ban, a class action was launched on behalf of thousands of women with the backing of US legal advocate Erin Brockovich.
Essure is no longer being manufactured or distributed. The manufacturer has been asked to undertake a post-market surveillance study by the FDA.
